Cardiogenic shock is well-recognized as one of the catastrophic acute heart failure
syndromes especially in the setting of an acute myocardial infarction. Even in the
era of early prompt coronary reperfusion with a conventional mechanical circulatory
support, systemic and myocardial tissue-level mal-perfusion have a critical role in
the fatal pathogenesis of a cardiogenic shock complicating acute myocardial infarction.
In 2017, the Impella system has been launched in Japan for a variety of acute cardiogenic
shocks. Using a miniaturized axial pump aspirating blood from the left ventricle (LV)
into the ascending aorta, the Impella system may decrease LV oxygen consumption and
synergistically preserve systemic perfusion. Here, I will address an overview of critical
issues and then think of the best challenges to provide better clinical outcomes using
this system in patients with a cardiogenic shock complicating acute myocardial infarction.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Cardiac FailureAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
